Glycomet-GP 2 Forte Tablet PR is a combination oral antidiabetic medication containing Glimepiride 2 mg and Metformin 1000 mg, primarily indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, functions by stimulating pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, acts by decreasing hepatic glucose production, improving peripheral glucose uptake, and enhancing insulin sensitivity. The combination of these two agents provides complementary mechanisms to effectively reduce blood glucose levels in patients inadequately controlled by diet and exercise alone. Glycomet-GP 2 Forte Tablet PR is typically prescribed when monotherapy with either agent is insufficient, offering improved glycemic control while minimizing the risk of hypoglycemia associated with sulfonylureas alone. The extended-release formulation ensures a sustained therapeutic effect, promoting better patient compliance through once-daily dosing. It is important to monitor renal function prior to and during therapy due to the risk of lactic acidosis associated with Metformin. Patients should be advised regarding potential side effects such as gastrointestinal disturbances, hypoglycemia, and rare allergic reactions. Glycomet-GP 2 Forte Tablet PR should be used as part of a comprehensive diabetes management plan including diet, exercise, and regular blood glucose monitoring.